EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876

Priya Ragunathan iD, Pearly Shuyi Ng, Samsher Singh iD, Wee Han Poh, Dennis Litty, Nitin Pal Kalia iD, Simon Larsson, Amaravadhi Harikishore iD, Scott A Rice, Philip W Ingham iD, Volker Müller iD, Garrett Moraski iD und 4 weitere

Microbiology Spectrum · 2023

DOI: 10.1128/spectrum.02282-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2023. Verfasst von Priya Ragunathan und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Nanyang Technological University , Singapore, Singapore. Hauptthemen laut MEDLINE: Clofazimine, Mycobacterium tuberculosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Research Foundation Singapore (NRF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Mycobacterium tuberculosis ( Mtb ) F-ATP synthase generates most of the biological energy currency ATP. Previously, we identified the mycobacterium-specific loop of the F-ATP synthase subunit γ as a new anti-tuberculosis target and discovered the novel diaminopyrimidine GaMF1, whose potency was improved by structure-activity relationship studies leading to the analog GaMF1.39. Here, we report that GaMF1.39 depletes cellular ATP formation by targeting the mycobacterial F-ATP synthase without affecting proton coupling or oxygen consumption. The antimycobacterial compound is bactericidal and potent against Mtb in macrophages without inducing phenotypic changes in biofilm formation, planktonic bacteria, or being toxic to zebrafish larvae. Combining GaMF1.39 with the NADH dehydrogenase inhibitor clofazimine, the cyt- bcc:aa 3 inhibitor Telacebec, or the F-ATP synthase inhibitor TBAJ-876 showed enhanced whole ATP synthesis inhibition and anti-tuberculosis activity. These results suggest that GaMF1.39 may add value to a compound combination targeting oxidative phosphorylation for tuberculosis treatment. IMPORTANCE New drugs are needed to combat multidrug-resistant tuberculosis. The electron transport chain (ETC) maintains the electrochemical potential across the cytoplasmic membrane and allows the production of ATP, the energy currency of any living cell. The mycobacterial engine F-ATP synthase catalyzes the formation of ATP and has come into focus as an attractive and rich drug target. Recent deep insights into these mycobacterial F 1 F O -ATP synthase elements opened the door for a renaissance of structure-based target identification and inhibitor design. In this study, we present the GaMF1.39 antimycobacterial compound, targeting the rotary subunit γ of the biological engine. The compound is bactericidal, inhibits infection ex vivo , and displays enhanced anti-tuberculosis activity in combination with ETC inhibitors, which promises new strategies to shorten tuberculosis chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClofazimineMycobacterium tuberculosisAntitubercular AgentsAdenosine TriphosphateDiarylquinolinesImidazolesPiperidinesPyridines

Stichwörter der Autor:innen

F-ATP synthaseMycobacterium tuberculosisanti-TB compoundbioenergeticsoxidative phosphorylationtuberculosis

Substanzen

ClofazimineAntitubercular AgentsAdenosine TriphosphateTBAJ-876DiarylquinolinestelacebecImidazolesPiperidinesPyridines

Autor:innen und Institutionen

  • School of Biological Sciences, Nanyang Technological University , Singapore, Singapore.
  • Experimental Drug Development Centre, Agency for Science, Technology and Research , Singapore, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Experimental Medicine Building , Singapore, Singapore.
  • Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University , Singapore, Singapore.
  • Molecular Microbiology and Bioenergetics, Institute for Molecular Biosciences, Johann Wolfgang Goethe University Frankfurt/Main , Frankfurt, Germany.
  • Department of Biological Sciences (Pharmacology & Toxicology), National Institute of Pharmaceutical Education and Research , Hyderabad, Telangana, India.

ORCID-Profile: Priya Ragunathan, Samsher Singh, Nitin Pal Kalia, Amaravadhi Harikishore, Philip W Ingham, Volker Müller, Garrett Moraski, Marvin J Miller, Thomas Dick, Kevin Pethe, Gerhard Grüber

Förderung

  • NIAID NIH HHS
  • National Research Foundation Singapore (NRF)

Zitieren

APA

Ragunathan, P., Shuyi Ng, P., Singh, S., Poh, W. H., Litty, D., Kalia, N. P., Larsson, S., Harikishore, A., Rice, S. A., Ingham, P. W., Müller, V., Moraski, G., Miller, M. J., Dick, T., Pethe, K., & Grüber, G. (2023). GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02282-23

Vancouver

Ragunathan P, Shuyi Ng P, Singh S, Poh WH, Litty D, Kalia NP, et al. GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876. Microbiology Spectrum. 2023. doi:10.1128/spectrum.02282-23

BibTeX
@article{Ragunathan2023,
  author = {Ragunathan, Priya and Shuyi Ng, Pearly and Singh, Samsher and Poh, Wee Han and Litty, Dennis and Kalia, Nitin Pal and Larsson, Simon and Harikishore, Amaravadhi and Rice, Scott A and Ingham, Philip W and Müller, Volker and Moraski, Garrett and Miller, Marvin J and Dick, Thomas and Pethe, Kevin and Grüber, Gerhard},
  title = {GaMF1.39’s antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876},
  journal = {Microbiology Spectrum},
  year = {2023},
  doi = {10.1128/spectrum.02282-23}
}
Kostenlos starten →